Login / Signup

GPER Agonist G-1 Disrupts Tubulin Dynamics and Potentiates Temozolomide to Impair Glioblastoma Cell Proliferation.

Alex HirtzNolwenn LebourdaisFabien RechYann BaillyAthénaïs VaginayMalika Smaïl-TabboneHélène Dubois-Pot-SchneiderHélène Dumond
Published in: Cells (2021)
Glioblastoma (GBM) is the most common brain tumor in adults, which is very aggressive, with a very poor prognosis that affects men twice as much as women, suggesting that female hormones (estrogen) play a protective role. With an in silico approach, we highlighted that the expression of the membrane G-protein-coupled estrogen receptor (GPER) had an impact on GBM female patient survival. In this context, we explored for the first time the role of the GPER agonist G-1 on GBM cell proliferation. Our results suggested that G-1 exposure had a cytostatic effect, leading to reversible G2/M arrest, due to tubulin polymerization blockade during mitosis. However, the observed effect was independent of GPER. Interestingly, G-1 potentiated the efficacy of temozolomide, the current standard chemotherapy treatment, since the combination of both treatments led to prolonged mitotic arrest, even in a temozolomide less-sensitive cell line. In conclusion, our results suggested that G-1, in combination with standard chemotherapy, might be a promising way to limit the progression and aggressiveness of GBM.
Keyphrases
  • estrogen receptor
  • poor prognosis
  • cell cycle
  • cell proliferation
  • long non coding rna
  • newly diagnosed
  • locally advanced
  • polycystic ovary syndrome
  • molecular docking
  • pregnant women
  • rectal cancer
  • insulin resistance